Twist Bioscience Corp (TWST)
NASDAQ:TWST
Want to see TWST full AI Analyst Report?
TWST Stock Chart & Stats
$59.81
-$0.78(-1.71%)
At close: 4:00 PM EST
$59.81
-$0.78(-1.71%)
Day’s Range― - ―
52-Week Range$23.30 - $66.06
Previous CloseN/A
Volume152.02K
Average Volume (3M)1.13M
Market Cap
$3.70B
Enterprise Value$3.42B
Total Cash (Recent Filing)$197.95M
Total Debt (Recent Filing)$183.86M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Jul 31, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding61,311,703
10 Day Avg. Volume1,242,343
30 Day Avg. Volume1,126,480
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue8.73
Enterprise Value/Gross Profit16.91
Enterprise Value/Ebitda-66.81
Forecast
1Y Price Target
$62.71Price Target Upside4.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$438.63M
Bulls Say, Bears Say
Bulls Say
Competitive PositioningInvestor interest in AI-driven drug discovery reinforces the company's position as a preferred provider of DNA synthesis and protein services, supporting expanded commercial demand.
Financial Performance And GuidanceRaised revenue guidance and quarterly results that exceeded expectations, along with gross margins above targets, strengthen confidence in revenue momentum and the path to adjusted profitability.
Partnerships And Platform ExpansionCo-exclusive license of the B-Body bispecific antibody platform broadens antibody discovery offerings and creates new service and licensing revenue streams.
Bears Say
Adjusted EBITDA And Cash BurnA larger-than-expected adjusted EBITDA loss versus consensus signals elevated cash burn and heightens investor concern about short-term financial resilience.
Execution Risk On New CapabilitiesInvestments in new wet-lab and discovery capabilities may not convert into expected customer contracts, delaying revenue realization and increasing execution risk.
Profitability PressureSignificant investment to scale capabilities for anticipated demand has depressed profitability, increasing uncertainty around near-term margin improvement.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was $23.30 and its highest was $66.06 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is $3.70B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is Jul 31, 2026 which is in 87 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on May 04, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.233.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.42.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 61,311,703 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -6.97%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.71 (4.86% Upside)
$62.71 (4.86% Upside)
Blogger Sentiment
Bullish
TWST Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.52%
12-Months-Change
Fundamentals
Return on Equity
-16.58%
Trailing 12-Months
Asset Growth
4.85%
Trailing 12-Months
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
TWST Company Deck
TWST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$62.71
▲(4.86% Upside)
Technical Analysis
Ownership Overview
3.05% Insiders
23.62% Mutual Funds
3.49% Other Institutional Investors
40.80% Public Companies and
Individual Investors